EUVIMEDEUVIMED entdecken
Crossref

Cancer risk in congenital heart disease survivors: The need for long-term screening strategies

Josephine Ushang Adie

Cancer Plus · 11.11.2026 · 026290043

DOI: 10.36922/cp026290043 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Plus, online erschienen am 11.11.2026. Verfasst von Josephine Ushang Adie.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Improved survival in congenital heart disease (CHD) has shifted attention toward acquired conditions that emerge across the life course, including cancer. This structured narrative review updates epidemiologic, mechanistic, and surveillance evidence through 2025 and proposes a practical framework for clinical risk assessment. A 2025 systematic review and meta-analysis of six observational studies involving 276,124 participants reported a pooled cancer hazard ratio of 1.71 (95% confidence interval: 1.28–2.28); the estimate remained elevated after adjustment for chromosomal abnormalities (1.54, 95% confidence interval: 1.24–1.91), although between-study heterogeneity was substantial. Large registry studies show that risk is not uniform: it is influenced by age, CHD complexity, early procedures, genetic syndromes, transplantation, and cumulative medical exposure. Potential mechanisms include ionizing radiation, chronic hypoxemia with hypoxia-inducible factor signaling and oxidative stress, Fontan-associated hepatic congestion and fibrosis, altered immune surveillance after thymectomy, shared developmental genetics, and modifiable lifestyle factors. No broad CHD-specific cancer screening guideline currently exists. This review therefore proposes a three-tier surveillance algorithm that preserves standard population screening for most survivors, adds structured annual risk review for those with cumulative exposures or complex physiology, and applies condition-specific surveillance for clearly defined high-risk groups, particularly Fontan-associated liver disease and genetic syndromes. The proposed framework is intended for prospective validation rather than immediate replacement of established national screening guidelines.

Zitieren

APA

Adie, J. U. (2026). Cancer risk in congenital heart disease survivors: The need for long-term screening strategies. Cancer Plus, 0(0), 026290043. https://doi.org/10.36922/cp026290043

Vancouver

Adie JU. Cancer risk in congenital heart disease survivors: The need for long-term screening strategies. Cancer Plus. 2026;0(0):026290043. doi:10.36922/cp026290043

BibTeX
@article{Adie2026,
  author = {Adie, Josephine Ushang},
  title = {Cancer risk in congenital heart disease survivors: The need for long-term screening strategies},
  journal = {Cancer Plus},
  year = {2026},
  volume = {0},
  number = {0},
  pages = {026290043},
  doi = {10.36922/cp026290043}
}
Kostenlos starten →